IMPORTANCE: Determining the annual rate of change in the width of the inner segment ellipsoid zone (EZ; ie, inner/outer segment border) in the context of short-term variability should allow us to better understand the value of this measure for future treatment trials in X-linked retinitis pigmentosa (XLRP). OBJECTIVES: To identify the width of the central region showing an EZ and to determine the short-term repeat variability and the annual rate of change in the width of the EZ from spectral-domain optical coherence tomography (SD-OCT) measures in RP. DESIGN:Patients with recessive or simplex RP (age range, 8-65 years; mean age, 40.5 years) underwent scanning twice on the same day to evaluate test-retest variability. Patients with XLRP (age range, 8-27 years; mean age, 15.2 years) from a larger group participating in an ongoing double-blind treatment trial (docosahexaenoic acid vs placebo; clinicaltrials.gov NCT00100230) underwent spectral-domain optical coherence tomography line scanning across the horizontal meridian at 3 yearly intervals. SETTING:Research center specializing in medical retina. PARTICIPANTS: Forty-eight patients with RP, including 20 with recessive or simplex RP and 28 with XLRP, and 23 healthy control subjects. MAIN OUTCOME AND MEASURE: Widths of the EZ calculated and compared among the 3 annual visits. RESULTS: Test-retest differences were normally distributed, and the magnitude of the difference was independent of mean EZ width. The mean (SD) for test-retest differences in EZ width was 0.08° (0.22°) (range, -0.30° to 0.60°). Thus, 95% of all test-retest differences fall within ± 0.43° (124 μm). Of the 28 patients with XLRP, 27 showed a significant decrease in EZ width after 2 years. Patients with XLRP showed a mean annual decrease in EZ width of 0.86° (248 μm, or 7%). CONCLUSIONS AND RELEVANCE: The mean rate of decline in EZ width (7%) translates into a mean rate of change of 13% for the equivalent area of functioning retina. This rate of change is consistent with that reported for visual fields and full-field electroretinograms. Unlike visual fields and electroretinograms, however, the repeat variability is less than the annual rate of change. These results support the validity of EZ width as an outcome measure in prospective clinical trials in RP.
RCT Entities:
IMPORTANCE: Determining the annual rate of change in the width of the inner segment ellipsoid zone (EZ; ie, inner/outer segment border) in the context of short-term variability should allow us to better understand the value of this measure for future treatment trials in X-linked retinitis pigmentosa (XLRP). OBJECTIVES: To identify the width of the central region showing an EZ and to determine the short-term repeat variability and the annual rate of change in the width of the EZ from spectral-domain optical coherence tomography (SD-OCT) measures in RP. DESIGN:Patients with recessive or simplex RP (age range, 8-65 years; mean age, 40.5 years) underwent scanning twice on the same day to evaluate test-retest variability. Patients with XLRP (age range, 8-27 years; mean age, 15.2 years) from a larger group participating in an ongoing double-blind treatment trial (docosahexaenoic acid vs placebo; clinicaltrials.gov NCT00100230) underwent spectral-domain optical coherence tomography line scanning across the horizontal meridian at 3 yearly intervals. SETTING: Research center specializing in medical retina. PARTICIPANTS: Forty-eight patients with RP, including 20 with recessive or simplex RP and 28 with XLRP, and 23 healthy control subjects. MAIN OUTCOME AND MEASURE: Widths of the EZ calculated and compared among the 3 annual visits. RESULTS: Test-retest differences were normally distributed, and the magnitude of the difference was independent of mean EZ width. The mean (SD) for test-retest differences in EZ width was 0.08° (0.22°) (range, -0.30° to 0.60°). Thus, 95% of all test-retest differences fall within ± 0.43° (124 μm). Of the 28 patients with XLRP, 27 showed a significant decrease in EZ width after 2 years. Patients with XLRP showed a mean annual decrease in EZ width of 0.86° (248 μm, or 7%). CONCLUSIONS AND RELEVANCE: The mean rate of decline in EZ width (7%) translates into a mean rate of change of 13% for the equivalent area of functioning retina. This rate of change is consistent with that reported for visual fields and full-field electroretinograms. Unlike visual fields and electroretinograms, however, the repeat variability is less than the annual rate of change. These results support the validity of EZ width as an outcome measure in prospective clinical trials in RP.
Authors: Margot A Lazow; Donald C Hood; Rithambara Ramachandran; Tomas R Burke; Yi-Zhong Wang; Vivienne C Greenstein; David G Birch Journal: Invest Ophthalmol Vis Sci Date: 2011-12-20 Impact factor: 4.799
Authors: Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Robert J Brockhurst; K C Hayes; Elizabeth J Johnson; Ellen J Anderson; Chris A Johnson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer Journal: Arch Ophthalmol Date: 2010-04
Authors: Dennis R Hoffman; Kirsten G Locke; Dianna H Wheaton; Gary E Fish; Rand Spencer; David G Birch Journal: Am J Ophthalmol Date: 2004-04 Impact factor: 5.258
Authors: Donald C Hood; Christine E Lin; Margot A Lazow; Kirsten G Locke; Xian Zhang; David G Birch Journal: Invest Ophthalmol Vis Sci Date: 2008-11-14 Impact factor: 4.799
Authors: Cindy X Cai; Kirsten G Locke; Rithambara Ramachandran; David G Birch; Donald C Hood Journal: Invest Ophthalmol Vis Sci Date: 2014-10-23 Impact factor: 4.799
Authors: Kelly Kiser; Kaylie D Webb-Jones; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; David G Birch Journal: Am J Ophthalmol Date: 2018-12-21 Impact factor: 5.258
Authors: Peter A Campochiaro; Mustafa Iftikhar; Gulnar Hafiz; Anam Akhlaq; Grace Tsai; Dagmar Wehling; Lili Lu; G Michael Wall; Mandeep S Singh; Xiangrong Kong Journal: J Clin Invest Date: 2020-03-02 Impact factor: 14.808
Authors: Ruben Jauregui; Karen Sophia Park; Jimmy K Duong; Janet R Sparrow; Stephen H Tsang Journal: Am J Ophthalmol Date: 2018-07-24 Impact factor: 5.258
Authors: David G Birch; Paul S Bernstein; Alessandro Iannacone; Mark E Pennesi; Byron L Lam; John Heckenlively; Karl Csaky; Mary Elizabeth Hartnett; Kevin L Winthrop; Thiran Jayasundera; Dianna K Hughbanks-Wheaton; Judith Warner; Paul Yang; Gary Edd Fish; Michael P Teske; Neal L Sklaver; Laura Erker; Elvira Chegarnov; Travis Smith; Aimee Wahle; Paul C VanVeldhuisen; Jennifer McCormack; Robert Lindblad; Steven Bramer; Stephen Rose; Patricia Zilliox; Peter J Francis; Richard G Weleber Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389